APICHOPE PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.89 CNY | +1.91% |
|
+7.16% | -23.27% |
| Sales 2023 * | 2.7B 372M | Sales 2024 * | 3.43B 474M | Capitalization | 10.28B 1.42B |
|---|---|---|---|---|---|
| Net income 2023 * | 349M 48.21M | Net income 2024 * | 459M 63.41M | EV / Sales 2023 * | 3.81 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2.99 x |
| P/E ratio 2023 * |
29.5
x | P/E ratio 2024 * |
22.4
x | Employees | 1,386 |
| Yield 2023 * |
0.28% | Yield 2024 * |
0.44% | Free-Float | 30.99% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.91% | ||
| 1 week | +7.16% | ||
| Current month | -9.88% | ||
| 1 month | -8.00% | ||
| 3 months | -5.22% | ||
| 6 months | -11.38% | ||
| Current year | -23.27% |
1 week
20.75
23.08
1 month
20.7126.39
Current year
17.5031.00
1 year
17.5034.34
3 years
14.6234.34
5 years
11.1034.34
10 years
7.5834.34
| Managers | Title | Age | Since |
|---|---|---|---|
Han Xiong Li
CEO | Chief Executive Officer | 50 | 02-02-03 |
Hui Xing Zhang
DFI | Director of Finance/CFO | 58 | 07-12-31 |
Dong Ling Yang
BRD | Director/Board Member | 57 | 03-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Han Xiong Li
CEO | Chief Executive Officer | 50 | 02-02-03 |
Han Dong Li
BRD | Director/Board Member | 56 | 02-12-31 |
Dong Ling Yang
BRD | Director/Board Member | 57 | 03-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 22.89 | +1.91% | 3,886,014 |
| 24-04-24 | 22.46 | +1.54% | 4,818,991 |
| 24-04-23 | 22.12 | +3.90% | 5,815,347 |
| 24-04-22 | 21.29 | +1.33% | 4,836,210 |
| 24-04-19 | 21.01 | -1.64% | 4,655,490 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotes
ApicHope Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of drugs. The Company has two types of products which are children's drugs and chronic disease drugs. The children's drugs are used for the treatment of colds, digestive anorexia, viral infections, children's eczema and other diseases, including clindamycin palmitate dispersible tablets and clindamycin palmitate granules. The chronic disease drugs include hepatocyte growth-promoting hormone for injection, aceglutamine for injection and adenosine cyclophosphate for injection, which are used for the treatment of severe viral hepatitis and cardiovascular and cerebrovascular diseases. The Company is also engaged in selling drugs for agents.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
22.89
CNY
Average target price
35.94
CNY
Spread / Average Target
+57.03%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.27% | 1.39B | |
| +18.59% | 22.25B | |
| +13.49% | 14.39B | |
| +12.83% | 13.55B | |
| +38.02% | 11.27B | |
| -9.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.01B | |
| -5.36% | 4.51B |
- Stock Market
- Equities
- 300723 Stock
